- NYSE: MRK has reported robust earnings for the third quarter, driven by a cancer therapy.
- Broader markets have been on the back foot due to the surge in covid cases.
- After weathering the storm, Merck has room to rise.
Markets are focused on coronavirus, but other diseases still grip the world – and Merck & Co., Inc.(NYSE: MRK) is set to benefit once the storm subsides. Shares of the New Jersey-based pharmaceutical giant have been on the back foot, falling by 1% on Tuesday. This slide is in line with the broader S&P 500 and other indexes, which are grappling with the spread of COVID-19 in Europe – and also in the US. The seven-day rolling average has surpassed 70,000 cases in America.
Merck and Co has been out of the spotlight in recent months, as other firms stood out in racing for a covid vaccine or therapeutics. However, the company still reported an increase in drug sales, mostly driven by a lung cancer immunotherapy treatment called Keytruda. Income from this medication jumped by 21% to $3.7 billion, beating estimates.
Moreover, MRK has upgraded its forecasts, saying it now projects a full-year adjusted profit of $5.91-$6.01 per share, with the bottom end of the range surpassing the previous top of the range – $5.78. The earnings report should help Merck weather the current market storm and push its shares higher.
On the other hand, the elections pose a risk to the pharmaceutical sector. Democrats have high chances of winning not on the White House but also the Senate. A President Joe Biden and with dominant Senators such as Bernie Sanders and Elisabeth Warren could work to lower drug prices. While Dems' priorities are first and foremost fiscal stimulus, they could reform healthcare later on, potentially weighing on pharma firms.
MRK Stock Forecast
NYSE: MRK has been sliding in the past month, and seems to have reached critical support at around $78.
It hit the same level last week and an attempt to break above $80 failed for now. The round $75 level is the next one to watch on the downside. Above $80, the next upside target is $83.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD: The hunt for the 0.7000 hurdle
AUD/USD quickly left behind Wednesday’s strong pullback and rose markedly past the 0.6900 barrier on Thursday, boosted by news of fresh stimulus in China as well as renewed weakness in the US Dollar.
EUR/USD rebounds on Thursday after midweek pullback
EUR/USD tuned back into the high end on Thursday, getting bolstered by a broad-market selloff in the Greenback. US data that printed better than expected helped to ease concerns of a possible economic slowdown within the US economy looming over the horizon.
Gold holding at higher ground at around $2,670
Gold breaks to new high of $2,673 on Thursday. Falling interest rates globally, intensifying geopolitical conflicts and heightened Fed easing bets are the main factors.
Ethereum investors show bullish bias amid ETF inflows and positive funding rates, exchange reserves pose risk
Ethereum traded around $2,640 on Thursday, up more than 2% following increased bullish bias among investors, as evidenced by ETH ETF net inflows and an uptrend in funding rates. However, investors may be wary of a potential correction from ETH's rising exchange reserve.
RBA widely expected to keep key interest rate unchanged amid persisting price pressures
The Reserve Bank of Australia is likely to continue bucking the trend adopted by major central banks of the dovish policy pivot, opting to maintain the policy for the seventh consecutive meeting on Tuesday.
Five best Forex brokers in 2024
VERIFIED Choosing the best Forex broker in 2024 requires careful consideration of certain essential factors. With the wide array of options available, it is crucial to find a broker that aligns with your trading style, experience level, and financial goals.